USV Private Limited

Let me verify the litigation context.

USV Private Limited ("USV," also styled USV Pvt Ltd) is a privately held Indian pharmaceutical company headquartered at Govandi East, Mumbai (Arvind Vithal Gandhi Chowk, BSD Marg). Incorporated in 1961 (CIN U24239MH1961PTC012098), it began as a joint venture with USV&P Inc. USA, then a Revlon subsidiary, and now operates independently. Shareholding is entirely promoter-family (Gandhi Tewari family) — it is not listed on any exchange. Size estimates vary by source: press and industry profiles put FY25 revenue at roughly ₹5,200 crore (~US$600M) with 7,000+ employees (Economic Times Pharma; Crustdata tracks ~5,965 employees; Tofler filings confirm ~6–9% annual sales growth).

USV manufactures and markets prescription pharmaceuticals, with leadership in oral anti-diabetic and cardiovascular therapies — brands include Glycomet/Glycomet GP, Jalra, Ecosprin and Roseday. It also has divisions in dermatology, gastroenterology, CNS, vitamins/nutraceuticals, and oncology. International operations supply small-molecule APIs and finished dosages to 65+ countries across seven Indian manufacturing plants (four formulations, two API, one biologicals), with US FDA, EMA and MHRA-accredited facilities. USV is the exclusive India partner for the German Sebamed skincare range, and in February 2026 agreed to acquire a 79% stake in D2C nutraceutical brand Wellbeing Nutrition.

Litigation posture: Operating company defending, not an NPE. The database shows one tracked case, with USV as defendant and zero plaintiff-side assertions — consistent with a generics/branded manufacturer facing Hatch-Waxman challenges rather than a patent assertion entity.

Notable case: Celgene Corporation v. USV Private Limited, No. 2:25-cv-06320 (D.N.J.), filed May 30, 2025 — an ANDA infringement action under 35 U.S.C. §271 concerning USV's Abbreviated New Drug Application No. 220322 and the Pomalyst (pomalidomide) product. Celgene asserted U.S. Patent Nos. 8,828,427; 9,993,467; and 10,555,939. The case closed November 6, 2025 via a stipulated consent judgment and injunction barring USV from marketing the ANDA product until the patents-in-suit expire (Patsnap Litigation Data; Dockets.Justia; Stanford NPE Litigation Database lists Celgene as a "product company" asserter). Venue was D. New Jersey, not a plaintiff-friendly Texas district.